Founded in 2004, DFINE, Inc. is a privately held medical device company dedicated to improving patient quality of life through the development of innovative, minimally invasive therapeutic devices used to treat pathologies of the vertebrae.

DFINE is the developer of Radiofrequency-Targeted Vertebral Augmentation™ (RF-TVA™), a novel approach to stabilizing vertebral compression fractures, relieving pain, and improving patient mobility. Performed with the company's flagship StabiliT® Vertebral Augmentation System, RF -TVA™ provides physicians greater control in the treatment of vertebral compression fractures through site- and size-specific cavity creation, ultra-high viscosity bone cement with extended working time, and a unique, remotely controlled cement delivery system.

DFINE recently received 510(k) clearance for the STAR™ Tumor Ablation System, a new product line designed for the palliative treatment of cancer patients. The product provides minimally invasive, localized tumor ablation for symptomatic spinal metastases, offering patients the potential for significant and immediate pain relief.

DFINE is based in San Jose, California.